USPSTF Issues Draft Recommendation Statement for Cervical Cancer Screening
TUESDAY, Dec. 10, 2024 -- The U.S. Preventive Services Task Force (USPSTF) recommends screening for cervical cancer, with different approaches recommended for those aged 21 to 29 years and 30 to 65 years. These recommendations form the basis of a draft recommendation statement published online Dec. 10.
Researchers from the Agency for Healthcare Research and Quality in Rockville, Maryland, conducted a systematic review to examine the comparative benefits and harms of high-risk human papillomavirus (hrHPV)-based screening strategies. Eighty-one fair- to good-quality studies reported in 118 publications were included. The researchers note that for participants aged 25 to 64 years, primary hrHPV screening with or without cytology triage can detect more cervical intraepithelial neoplasia 3+ in one round of screening compared with cytology with or without hrHPV triage. In a technical report, the guidelines-based strategy of three-year cytology alone from ages 21 to 65 years was not efficient, while several cotesting scenarios were on the efficiency frontier, and efficient strategies mainly involved five-year HPV testing starting at ages 25 or 30 years.
Based on these findings, the USPSTF recommends cervical cancer screening every three years with cervical cytology alone in women ages 21 to 29 years and every five years with hrHPV primary screening for women aged 30 to 65 years (A recommendation). For women aged 30 to 65 years, the USPSTF recommends continued screening every three years with cervical cytology alone or screening every five years with hrHPV testing combined with cytology as an alternative to primary screening (A recommendation).
The draft recommendation statement and evidence review have been posted for public comment. Comments can be submitted from Dec. 10, 2024, through Jan. 13, 2025.
Draft Recommendation Statement
Comment on Recommendation Statement
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Read this next
Features of Immunesenescence Present in Early Stages of Rheumatoid Arthritis
THURSDAY, Sept. 11, 2025 -- Some features of immunesenescence are present in the very early stages of rheumatoid arthritis (RA), according to a study published online Sept. 3 in...
Urine Biomarker Panel Sensitive, Specific for Prostate Cancer Diagnosis
THURSDAY, Sept. 11, 2025 -- A urine-based biomarker panel has high accuracy for diagnosing prostate cancer (PCa), according to a study published in the September issue of...
Hospitals Vary in Their Definition of Blood Culture Contamination
THURSDAY, Sept. 11, 2025 -- U.S. hospitals vary in how they define blood culture contamination (BCC), according to a study published online July 11 in the Journal of Clinical...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.